Photo from wikipedia
Key Points • In relapsed or refractory AML, mutated NPM1 has no impact on the risk of relapse or death.• The addition of venetoclax to salvage treatment for NPM1-mutated AML… Click to show full abstract
Key Points • In relapsed or refractory AML, mutated NPM1 has no impact on the risk of relapse or death.• The addition of venetoclax to salvage treatment for NPM1-mutated AML is associated with improved outcomes.
Keywords:
refractory aml;
clinical outcomes;
associated npm1;
npm1 mutations;
outcomes associated;
relapsed refractory
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!